Assay development & optimisation

In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples. This approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression. ATTRv amyloidosis, caused by mutation of the transthyretin protein is […]

BioIVT, provider of research models and services for drug and diagnostic development, is supplying peripheral blood mononuclear cells (PBMCs) for Promega’s antibody-dependent Cellular Cytotoxicity (ADCC) bioassay bioassay, which uses PBMCs to mimic in vivo conditions and measure the ADCC of antibodies during drug development and characterisation. “This new platform combines BioIVT’s high quality, physiologically representative PBMCs with […]

PerkinElmer has announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery. The new offerings extend the company’s GPCR analysis portfolio, which includes assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORF libraries to help scientists more easily and accurately characterise receptors, screen […]

Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs evaluation are time consuming. Furthermore, […]

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany. The Clinical Laboratory Science (CLS) team in Marburg, […]

Eurofins Discovery is a CRO with a range of expertise in drug discovery. Christina Shasserre, Senior VP spoke to Lu Rahman about some of the company’s current COVID-related work as well as offering insight into the drug discovery landscape.   LR: Are you able to share some of Eurofins Discovery’s recent projects? CS: As we […]

Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech offers five challenges and solutions for optimal assay development in drug discovery Developing a suitable assay is critical to identifying and characterising novel drug leads. While designing an assay may appear straightforward, developing the assay in an optimised format for a particular target and project can become […]

We understand the importance of kinetic assay design. In the upcoming DDW collaboration, supported by SPT Labtech, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience, will share his pharmacology expertise to explain how to produce assays that deliver hits with higher physiological relevance. Due to popularity we have opened up additional spaces on this exclusive […]

DDW is delighted to announce an exclusive event, supported by SPT Labtech, that will allow you to gain knowledge on kinetic assay design and take this forward to produce assays that deliver hits with higher physiological relevance. Pharmacology expert Dr Nick Holliday, chief scientific officer, Excellerate Bioscience, will lead this session that will focus on […]

In an exclusive event for DDW, Dr Holliday, Chief Scientific Officer, Excellerate Bioscience, will focus on the importance of kinetic assays in drug discovery. What you will learn: How association and dissociation rate constants describe compound binding kinetics The potential clinical benefits of optimising kinetic constants when compound profiling The wider relevance of signalling kinetics […]